Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Frederick Porter · DUKE UNIVERSITY · 2022 · $5,274,388 — Project 2: Current Good Manufacture Practices (CGMP) Production of Nucleoside-Modified mRNAs Encoding HIV-1 Envelopes This IPCAVD grant seeks to develop and evaluate mRNA as an HIV-1 vaccine platform. Project 2 will oversee the manufacture of two nucleoside-modified mRNAs by current good manufacturi…
Richard Thomas Wyatt · SCRIPPS RESEARCH INSTITUTE, THE · 2022 · $214,021 — The Administrative Core A, led by Dr. Richard Wyatt, will administer support for Projects 1 and 2 and Cores B and C, under the umbrella of this new HIVRAD proposal. This Core will coordinate an administrative partnership plan to maintain good communications within the HIVRAD working group and releva…
Boris Dominik Juelg · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · 2022 · $470,796 — Project 2: Summary While traditionally regarded as a generalized tolerogenic state, emerging data suggest that pregnancy is far from a simple anti-inflammatory shift but is characterized by dramatic shifts from inflammation to tolerance over the course of pregnancy, to accommodate changes in the …
Barton F. Haynes · DUKE UNIVERSITY · 2022 · $2,099,464 — Project 1: Development of Nucleoside-Modified mRNAs Encoding Sequential HIV-1 Envelopes for Initiation of V3-glycan Neutralizing Antibody Lineages A major goal of HIV-1 vaccine development is to induce broadly neutralizing antibodies (bnAbs). This IPCAVD team has immunogens that can trigger unmutate…
Deborah H. Fuller · NORTHERN ARIZONA UNIVERSITY · 2022 · $442,828 — SUMMARY Coccidioidomycosis, also known as Valley Fever (VF) impacts residents in arid regions of the world including southwestern US, areas in South and Central America and in Mexico. Annual incidences are rising overall with estimated increases in recent years of more than 200% in some areas. In ad…
CHIUNG-YU HUNG · UNIVERSITY OF TEXAS SAN ANTONIO · 2022 · $387,539 — Project Summary An estimated 350,000 people in the United States become infected with Coccidioides annually. There is an unmet need to develop better chemotherapies and a vaccine for active immunization and/or immunotherapy against coccidioidomycosis (CM). We have previously created a recombinant ch…
Purveshkumar Khatri · STANFORD UNIVERSITY · 2022 · $309,746 — ABSTRACT – Data Management and Analysis Core. Identifying the biological features of the human immune response that correlate with and predict the development of an effective immune response to vaccination is an overarching goal of this U19 consortium. The Data Management and Analysis Core (DMAC) in…
BARBARA K FELBER · DIVISION OF BASIC SCIENCES - NCI · 2022 · $704,873 — We have been studying the immune response of COVID-19 cohorts longitudinally to characterize the nature and longevity of immune response (Rosati M, Am J Hematol: 97:E3, 2022; Rosati Frontiers Immunol 12: 793953, 2021; Thomopoulos, Viruses 1:1844; 2021; Terpos, Eur J Intern Med, 89:87,…
Kari C. Nadeau · STANFORD UNIVERSITY · 2022 · $309,746 — 1 ABSTRACT – Clinical Core 2 The Clinical Core of the Stanford HIPC U19 will provide state-of-the-art clinical and biospecimen support for all 3 the research projects, the Immune Monitoring and the Data Management and Analysis Cores, as well as the 4 expertise, facilities, personnel, procedures a…
PETER SARNOW · STANFORD UNIVERSITY · 2022 · $4,810,759 — ABSTRACT The overall objective of this project is to use an integrated, multidisciplinary research endeavor that brings together investigators with expertise in diverse areas to advance the development of novel targets, therapeutic strategies, and delivery methods to treat viral pathogens of pandemi…
Joanna Phillips · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · 2022 · $180,968 — PROJECT SUMMARY The UCSF Brain Tumor SPORE Biospecimen/Pathology Core provides staff and technology dedicated to the procurement, processing, storing, distribution, and histopathologic analysis of high-quality brain tumor biospecimens for translational science research. Our mission is to enhance bio…
Bart Nolan Ford · OSU CENTER FOR HEALTH SCIENCES · 2022 · $133,636 — Abstract The lifelong influence of adversity during development on gene regulation in the immune system offers insight into COVID-19 related health disparities. However, the pathways by which adverse childhood experiences (ACEs) disrupt immune function throughout life are not fully understood and it…
Michael Gale · OREGON HEALTH & SCIENCE UNIVERSITY · 2022 · $1,063,373 — CORE D PROJECT SUMMARY The `Omics, Bioinformatics, and Data Management Core (Core D) serves this Program by providing high resolution functional genomics and bioinformatics computation analyses with statistical integration. The main objective of the Core is to define the gene expression signatures a…
Beth Ann Tamburini · UNIVERSITY OF COLORADO DENVER · 2023 · $459,647 — Project summary: We and others have demonstrated that antigens derived from infectious viral infections persist in the host for extended periods of time, well beyond the time in which the infection is cleared from the host. Our lab has specifically identified that antigens derived from both vaccinat…
Yizhou Dong · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · 2023 · $778,064 — PROJECT SUMMARY A vaccine is a promising approach for stopping the spread of HIV infections. Although vaccine regimens in clinical trials show various levels of protection against HIV, there is no effective vaccine available for a large population yet. Preclinical and clinical data demonstrate the i…
DENNIS J. HARTIGAN-O'CONNOR · TENDEL THERAPIES INC. · 2023 · $300,930 — This project will test the ability of T follicular helper (Tfh) cell-targeting “genetic adjuvants” to improve immunogenicity of an advanced HIV envelope (Env) trimer. Eliciting neutralizing antibodies (nAb) against HIV will likely be required to create effective therapeutic vaccines that attenuate H…
Jeremy Phillip Kamil · LOUISIANA STATE UNIV HSC SHREVEPORT · 2023 · $416,803 — This project focuses on the role of glycobiology in human cytomegalovirus (HCMV) immune evasion strategies. Our long-term goal is to understand how the virus exploits host protein glycosylation pathways to shield its virions and decorate the surfaces of infected cells with oligosaccharide patterns t…
Denise L. Doolan · UNIVERSITY OF QUEENSLAND · 2023 · $487,101 — PA-19-077 DOOLAN: PROJECT SUMMARY Malaria remains a global public health problem with nearly half of the world's population at risk. An effective malaria vaccine would prevent almost half a million deaths and over 200 million clinical cases each year and help eradicate the disease. The most effectiv…
MIKELL PAIGE · GEORGE MASON UNIVERSITY · 2023 · $498,828 — PROJECT SUMMARY mRNA vaccines have received emergency authorization approval for Covid-19 and are under development for several other infectious diseases. The mRNA-encoded immunogen in these vaccines is delivered inside a lipid nanoparticle (LNP) that comprises four lipids, the most important being …
Jared Paul May · UNIVERSITY OF MISSOURI KANSAS CITY · 2023 · $78,250 — This proposal will investigate the role severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) N protein phase separation in disrupting cellular translation and RNA metabolism. N protein phase separation creates membraneless organelles and concentrates RNAs in a droplet (dense) phase. While N …